TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07670650: PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocy

Sponsor: University of Florida · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 108 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$12,933,360

Rescue Site Savings

+$8,524,260

Unlock Full NCT07670650 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07670650 Rescue Dossier →